Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN22 | Q9Y2R2 | 3/20 | 0.53 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907114 | 1.00 | PTPN22 (0.53) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL17040401 | 0.87 | PTPN22 (0.56) | PTPN22PTPN12KMT2A | |
| SCHEMBL13056346 | 0.86 | PTPN22 (0.67) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL17040402 | 0.86 | PTPN22 (0.55) | PTPN22PTPN12KMT2A | |
| SCHEMBL12673226 | 0.84 | PTPN22 (0.53) | PTPN22KMT2AMEN1MAPTKDM4E | |
| SCHEMBL13326247 | 0.81 | PTPN22 (0.62) | PTPN22PTPN12KMT2AMEN1MAPT | |
| SCHEMBL12672984 | 0.79 | PTPN22 (0.53) | PTPN22PTPN12KMT2A | |
| SCHEMBL13056341 | 0.75 | PTPN22 (0.70) | PTPN22PTPN12KMT2AMEN1POLB | |
| SCHEMBL15330386 | 0.73 | PTPN12 (0.79) | PTPN22PTPN12KMT2AMEN1MMP3 | |
| SCHEMBL15330387 | 0.73 | PTPN12 (0.79) | PTPN22PTPN12KMT2AMEN1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947717-B2 | Inhibitors of lethal factor protease | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | THE BURNHAM INSTITUTE (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016292-A1 | INHIBITORS OF LETHAL FACTOR PROTEASE | APAF1, F11, SERPINB1 | PTPN22 2193/4885PTPN12 1970/4885KMT2A 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.